サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1379019

ワクチン受託製造市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Vaccine Contract Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 147 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.85円
ワクチン受託製造市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界のワクチン受託製造市場は2022年に25億米ドルに達しました。今後、IMARCグループは、2022年から2028年にかけて10.3%の成長率（CAGR）を示し、2028年までに45億米ドルに達すると予測しています。

ワクチン受託製造とは、ワクチンの大量生産を製造受託機関（CMO）に委託することです。これらの組織は、プレフォーミュレーション業務、製剤開発、製法開発、安定性試験、前臨床活動、登録バッチ、商業製造を含む数多くのサービスを提供しています。これとは別に、製薬会社の生産チェーンを拡大するための専門知識や革新的な技術も提供しています。現在、開発コストの削減と複雑な製造プロトコルを理由に、ワクチン製造業務のアウトソーシングに対する需要が世界中で高まっています。

ワクチン接種は、動物だけでなく人間の健康増進にも極めて重要な役割を果たしています。抗生物質の必要性を減らし、病気を予防します。ワクチン接種に対する意識の高まりと、重篤な病気や感染症から身を守るといった多くの関連メリットが、予防接種プログラムや予防接種の需要を喚起しています。このことは、製造に必要な資本の複雑さを理解することと相まって、大手製薬会社をワクチン製造のアウトソーシングへと導いています。これとは別に、低資源国におけるワクチン製造のための設備や熟練労働者の不足も、世界のワクチン受託製造市場の成長に寄与しています。さらに、EB66やGPExのような発現システムや細胞培養培地プラットフォームのイントロダクションを含む技術の進歩が、市場の成長を支えています。さらに、多くの国々でコロナウイルス感染症（COVID-19）の症例が憂慮すべきほど増加していることから、ワクチン開発企業はCMOと業務委託契約を結ぶようになりました。このことは、市場の成長に有利な見通しを生み出しています。

本レポートで扱う主な質問

  • 世界のワクチン受託製造市場はこれまでどのように推移してきたか？
  • COVID-19が世界のワクチン受託製造市場に与えた影響は？
  • 主要な地域市場は？
  • ワクチンタイプによる市場内訳は？
  • ワークフローに基づく市場内訳は？
  • 用途別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主な促進要因と課題は？
  • 世界のワクチン受託製造市場の構造と主要プレーヤーは？
  • 業界における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のワクチン受託製造市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：ワクチンタイプ別

  • 弱毒ワクチン
    • 市場動向
    • 市場予測
  • 不活化ワクチン
    • 市場動向
    • 市場予測
  • サブユニットベース
    • 市場動向
    • 市場予測
  • トキソイドベース
    • 市場動向
    • 市場予測
  • DNAベース
    • 市場動向
    • 市場予測

第7章 市場内訳：ワークフロー別

  • ダウンストリーム
    • 市場動向
    • 主要セグメント
      • 充填・仕上げ作業
      • 分析・QC
      • パッケージング
    • 市場予測
  • アップストリーム
    • 市場動向
    • 主要セグメント
      • 哺乳類発現システム
      • 細菌発現システム
      • 酵母発現システム
      • バキュロウイルス/昆虫発現システム
      • その他
    • 市場予測

第8章 市場内訳：用途別

  • ヒト
    • 市場動向
    • 市場予測
  • 動物
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Ajinomoto Co. Inc.
    • Albany Molecular Research Inc
    • Catalent Inc
    • Cobra Biologics Limited（Charles River Laboratories International Inc.）
    • Cytovance Biologics Inc.（Hepalink USA Inc.）
    • Fujifilm Holdings Corporation
    • ICON plc
    • IDT Biologika GmbH
    • Lonza Group AG
    • Merck KGaA
    • Pharmaceutical Product Development LLC
    • PRA Health Sciences Inc.
図表

List of Figures

  • Figure 1: Global: Vaccine Contract Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Contract Manufacturing Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Vaccine Contract Manufacturing Market: Breakup by Vaccine Type (in %), 2022
  • Figure 5: Global: Vaccine Contract Manufacturing Market: Breakup by Workflow (in %), 2022
  • Figure 6: Global: Vaccine Contract Manufacturing Market: Breakup by Application (in %), 2022
  • Figure 7: Global: Vaccine Contract Manufacturing Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Vaccine Contract Manufacturing (Attenuated) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Vaccine Contract Manufacturing (Attenuated) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Vaccine Contract Manufacturing (Inactivated) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Vaccine Contract Manufacturing (Inactivated) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Vaccine Contract Manufacturing (Subunit-based) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Vaccine Contract Manufacturing (Subunit-based) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Vaccine Contract Manufacturing (Toxoid-based) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Vaccine Contract Manufacturing (Toxoid-based) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Vaccine Contract Manufacturing (DNA-based) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Vaccine Contract Manufacturing (DNA-based) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Vaccine Contract Manufacturing (Downstream) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Vaccine Contract Manufacturing (Downstream) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Vaccine Contract Manufacturing (Upstream) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Vaccine Contract Manufacturing (Upstream) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Vaccine Contract Manufacturing (Human Use) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Vaccine Contract Manufacturing (Human Use) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Vaccine Contract Manufacturing (Veterinary) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Vaccine Contract Manufacturing (Veterinary) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: North America: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: North America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: United States: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: United States: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Canada: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Canada: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Asia-Pacific: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Asia-Pacific: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: China: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: China: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Japan: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Japan: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: India: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: India: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: South Korea: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: South Korea: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Australia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Australia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Indonesia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Indonesia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Europe: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Europe: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Germany: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Germany: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: France: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: France: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: United Kingdom: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: United Kingdom: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Italy: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Italy: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Spain: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Spain: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Russia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Russia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Latin America: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Latin America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Brazil: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Brazil: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Mexico: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Mexico: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Middle East and Africa: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Middle East and Africa: Vaccine Contract Manufacturing Market: Breakup by Country (in %), 2022
  • Figure 74: Middle East and Africa: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Global: Vaccine Contract Manufacturing Industry: SWOT Analysis
  • Figure 76: Global: Vaccine Contract Manufacturing Industry: Value Chain Analysis
  • Figure 77: Global: Vaccine Contract Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Contract Manufacturing Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Vaccine Type (in Million US$), 2023-2028
  • Table 3: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Workflow (in Million US$), 2023-2028
  • Table 4: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 5: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Vaccine Contract Manufacturing Market: Competitive Structure
  • Table 7: Global: Vaccine Contract Manufacturing Market: Key Players
目次
Product Code: SR112023A3872

Abstract

The global vaccine contract manufacturing market reached US$ 2.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2028, exhibiting a growth rate (CAGR) of 10.3% during 2022-2028.

Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols.

Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine contract manufacturing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on vaccine type, workflow and application.

Breakup by Vaccine Type:

Attenuated

Inactivated

Subunit-based

Toxoid-based

DNA-based

Breakup by Workflow:

Downstream

Fill and Finish Operations

Analytical and QC Studies

Packaging

Upstream

Mammalian Expression Systems

Bacterial Expression Systems

Yeast Expression Systems

Baculovirus/Insect Expression Systems

Others

Breakup by Application:

Human Use

Veterinary

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc.

Key Questions Answered in This Report:

  • How has the global vaccine contract manufacturing market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global vaccine contract manufacturing market?
  • What are the key regional markets?
  • What is the breakup of the market based on the vaccine type?
  • What is the breakup of the market based on the workflow?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global vaccine contract manufacturing market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Contract Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Attenuated
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Inactivated
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Subunit-based
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Toxoid-based
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 DNA-based
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Workflow

  • 7.1 Downstream
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Fill and Finish Operations
      • 7.1.2.2 Analytical and QC studies
      • 7.1.2.3 Packaging
    • 7.1.3 Market Forecast
  • 7.2 Upstream
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Mammalian Expression Systems
      • 7.2.2.2 Bacterial Expression Systems
      • 7.2.2.3 Yeast Expression Systems
      • 7.2.2.4 Baculovirus/Insect Expression Systems
      • 7.2.2.5 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Application

  • 8.1 Human Use
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Veterinary
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Ajinomoto Co. Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Albany Molecular Research Inc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Catalent Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Fujifilm Holdings Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 ICON plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 IDT Biologika GmbH
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lonza Group AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pharmaceutical Product Development LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 PRA Health Sciences Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials